July 2005 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

July 2005

Pharmaceutical Technology


The group also is exploring how various molecules affect the self-assembly chemistry and how to make the spheres monodispersive. "We're now trying to make the chemistry such that the spheres will all be the same size. And we're on the right track," says Wong.

Kaylynn Chiarello

1An in-depth discussion of the methodology is presented elsewhere (Adv. Mater. 17, 1145-1150 [2005]).

FORMULATION

It Helps to be Flexible: Supple WIN Compounds Could Cure the Common Cold

A wiggling WIN antiviral compound (which received its name from the former Sterling-Winthrop company) could be the answer for fighting the common cold, says a team of Purdue University (West Lafayette, IN, http://www.purdue.edu/) researchers.

The rhinovirus—one cause for the common cold—has two main properties that make it difficult to stop. First, the virus can go incognito by subtly changing its surface structure and making it undetectable by the body's immune system. Second, after the virus enters the cell, it opens up a trap door to unleash RNA that instructs the cell to produce more rhinovirus particles.

A small, cigar-shaped cavity located in the folds of the VP-1 protein on the viral shell helps guide these changes. Filling this crevice prevents the virus from shape shifting and is the key to curing the cold, say the Purdue researchers. "What we'd like to do is find something that will stabilize these VP-1 proteins so the trap door can't open, and WIN compounds are potential compounds for the job," said Carol B. Post, professor at Purdue, in a press release.

By using computer simulations of the molecule's structure, the team has discovered that the WIN compound's flexible nature allows it to wiggle into this gap. Once inside the cavity, the molecule affects the VP-1 protein's rigidity, thereby deactivating the virus. Said Post, "In essence, the compounds can get tangled up in the protein so it can't move enough to let the RNA out. One reason WIN compounds are promising is that they are very good at getting to the spot where they can tangle up the protein effectively, which turns out to be a tricky business."

Researchers speculate the stiffness may also inhibit the virus from opening its trap door because, just as people don't like exercising after a big meal, "having a WIN compound in its cavity may be the VP-1 protein's equivalent of having an overly full stomach," noted Post.

Kaylynn Chiarello


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here